{"id":54748,"date":"2026-01-20T00:19:42","date_gmt":"2026-01-19T16:19:42","guid":{"rendered":"https:\/\/flcube.com\/?p=54748"},"modified":"2026-01-20T00:19:43","modified_gmt":"2026-01-19T16:19:43","slug":"astrazeneca-secures-full-global-rights-to-abelzetas-c-car031-in-630m-car-t-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54748","title":{"rendered":"AstraZeneca Secures Full Global Rights to AbelZeta\u2019s C\u2011CAR031 in $630M CAR\u2011T Deal"},"content":{"rendered":"\n<p><strong>AbelZeta Pharma, Inc.<\/strong> (Sino\u2011US biotech) announced an agreement with <strong>AstraZeneca<\/strong> (AZ, <a href=\"https:\/\/www.google.com\/finance\/quote\/NVS:NYSE\">NASDAQ:\u202fAZN<\/a>) granting AZ the <strong>remaining 50% China rights<\/strong> for <strong>C\u2011CAR031<\/strong>, an <strong>autologous GPC3\u2011targeting CAR\u2011T therapy<\/strong>, giving AZ <strong>exclusive global development, manufacturing, and commercialization rights<\/strong>. The deal values the GPC3 program at up to <strong>USD\u202f630\u202fmillion<\/strong>, including an undisclosed upfront payment and milestones.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>AbelZeta Pharma (licensor) and AstraZeneca (licensee)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>C\u2011CAR031 (autologous GPC3\u2011targeting CAR\u2011T)<\/td><\/tr><tr><td><strong>Rights Acquired<\/strong><\/td><td>Remaining 50% China rights \u2192 <strong>exclusive global rights<\/strong><\/td><\/tr><tr><td><strong>Prior Agreement<\/strong><\/td><td>AZ already held RoW rights; now gains <strong>China<\/strong> and <strong>full global control<\/strong><\/td><\/tr><tr><td>**Financial Terms<\/td><td>Up to <strong>USD\u202f630\u202fmillion<\/strong> comprising:<br>\u2022 Undisclosed upfront payment<br>\u2022 Development, regulatory, and sales milestones<br>\u2022 Additional milestones + royalties for ex\u2011China development<\/td><\/tr><tr><td>**Technology<\/td><td>AZ\u2019s <strong>dnTGF\u03b2RII armored platform<\/strong> (dominant\u2011negative TGF\u2011\u03b2 receptor II)<\/td><\/tr><tr><td>**Indications<\/td><td>Hepatocellular carcinoma (HCC) and other solid tumors<\/td><\/tr><tr><td>**Clinical Stage<\/td><td>Ongoing clinical studies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> <strong>Glypican\u20113 (GPC3)<\/strong> \u2013 highly expressed on HCC and certain solid tumors, minimal expression on normal tissue<\/li>\n\n\n\n<li><strong>Platform:<\/strong> <strong>dnTGF\u03b2RII armored CAR\u2011T<\/strong> \u2013 engineered to <strong>resist TGF\u2011\u03b2 immunosuppression<\/strong> in the tumor microenvironment, enhancing persistence and efficacy<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> <strong>First CAR\u2011T<\/strong> leveraging AZ\u2019s proprietary armored platform for <strong>solid tumors<\/strong>, addressing a major unmet need beyond hematologic malignancies<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Solid tumor CAR\u2011T remains <strong>elusive<\/strong>; GPC3 target and TGF\u2011\u03b2 resistance could <strong>overcome key barriers<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>HCC Incidence (Annual)<\/strong><\/td><td>410,000<\/td><td>900,000<\/td><\/tr><tr><td><strong>GPC3\u2011Positive HCC<\/strong><\/td><td>280,000<\/td><td>630,000<\/td><\/tr><tr><td><strong>3L+ HCC Patients (2030E)<\/strong><\/td><td>85,000<\/td><td>190,000<\/td><\/tr><tr><td><strong>CAR\u2011T Penetration in Solid Tumors<\/strong><\/td><td>&lt;1\u202f%<\/td><td>&lt;1\u202f%<\/td><\/tr><tr><td><strong>Addressable Market (2030E)<\/strong><\/td><td>\u00a512\u202fbillion<\/td><td>$8.5\u202fbillion<\/td><\/tr><tr><td><strong>C\u2011CAR031 Peak Revenue (2032E)<\/strong><\/td><td>\u00a53.8\u202fbillion<\/td><td>$2.6\u202fbillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CAR\u2011T in HCC:<\/strong> <strong>No approved therapies<\/strong>; <strong>multiple failures<\/strong> (e.g., GPC3 CAR\u2011T from other developers)<\/li>\n\n\n\n<li><strong>CAR\u2011T in Solid Tumors:<\/strong> <strong>Limited success<\/strong>; TGF\u2011\u03b2 armoring is a <strong>key differentiator<\/strong><\/li>\n\n\n\n<li><strong>Standard of Care:<\/strong> <strong>Lenvima + Keytruda<\/strong> (1L), <strong>Atezolizumab + Bevacizumab<\/strong> (1L) \u2013 limited 3L+ options<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For AstraZeneca:<\/strong><\/li>\n\n\n\n<li><strong>Full global control<\/strong> enables <strong>unified development strategy<\/strong> and <strong>optimized manufacturing<\/strong><\/li>\n\n\n\n<li><strong>China market access<\/strong> via the acquisition accelerates <strong>NRDL pathway<\/strong> and commercial launch<\/li>\n\n\n\n<li><strong>Platform validation:<\/strong> Success could unlock <strong>dnTGF\u03b2RII platform<\/strong> for <strong>other solid tumor CAR\u2011Ts<\/strong><\/li>\n\n\n\n<li><strong>For AbelZeta:<\/strong><\/li>\n\n\n\n<li><strong>Up to $630M<\/strong> provides <strong>non\u2011dilutive funding<\/strong> for earlier\u2011stage pipeline (e.g., <strong>C\u2011CAR039<\/strong>, <strong>C\u2011CAR05<\/strong>)<\/li>\n\n\n\n<li><strong>Retains<\/strong> rights to <strong>receive milestones and royalties<\/strong> on global sales, ensuring <strong>long\u2011term value capture<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding deal completion, clinical development timelines, and commercial projections for C\u2011CAR031. Actual results may differ due to clinical trial outcomes, regulatory approvals, and competitive dynamics in the solid tumor CAR\u2011T space.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AbelZeta Pharma, Inc. (Sino\u2011US biotech) announced an agreement with AstraZeneca (AZ, NASDAQ:\u202fAZN) granting AZ the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":54751,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[837,130,16,21,77,871],"class_list":["post-54748","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-abelzeta-pharma","tag-astrazeneca","tag-cancer","tag-car-t","tag-cell-therapy","tag-nasdaq-azn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraZeneca Secures Full Global Rights to AbelZeta\u2019s C\u2011CAR031 in $630M CAR\u2011T Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AbelZeta Pharma, Inc. (Sino\u2011US biotech) announced an agreement with AstraZeneca (AZ, NASDAQ:\u202fAZN) granting AZ the remaining 50% China rights for C\u2011CAR031, an autologous GPC3\u2011targeting CAR\u2011T therapy, giving AZ exclusive global development, manufacturing, and commercialization rights. The deal values the GPC3 program at up to USD\u202f630\u202fmillion, including an undisclosed upfront payment and milestones.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54748\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca Secures Full Global Rights to AbelZeta\u2019s C\u2011CAR031 in $630M CAR\u2011T Deal\" \/>\n<meta property=\"og:description\" content=\"AbelZeta Pharma, Inc. (Sino\u2011US biotech) announced an agreement with AstraZeneca (AZ, NASDAQ:\u202fAZN) granting AZ the remaining 50% China rights for C\u2011CAR031, an autologous GPC3\u2011targeting CAR\u2011T therapy, giving AZ exclusive global development, manufacturing, and commercialization rights. The deal values the GPC3 program at up to USD\u202f630\u202fmillion, including an undisclosed upfront payment and milestones.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54748\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-19T16:19:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-19T16:19:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1901-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54748#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54748\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca Secures Full Global Rights to AbelZeta\u2019s C\u2011CAR031 in $630M CAR\u2011T Deal\",\"datePublished\":\"2026-01-19T16:19:42+00:00\",\"dateModified\":\"2026-01-19T16:19:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54748\"},\"wordCount\":438,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54748#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1901-1.webp\",\"keywords\":[\"AbelZeta Pharma\",\"AstraZeneca\",\"Cancer\",\"CAR-T\",\"Cell-therapy\",\"NASDAQ: AZN\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54748#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54748\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54748\",\"name\":\"AstraZeneca Secures Full Global Rights to AbelZeta\u2019s C\u2011CAR031 in $630M CAR\u2011T Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54748#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54748#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1901-1.webp\",\"datePublished\":\"2026-01-19T16:19:42+00:00\",\"dateModified\":\"2026-01-19T16:19:43+00:00\",\"description\":\"AbelZeta Pharma, Inc. (Sino\u2011US biotech) announced an agreement with AstraZeneca (AZ, NASDAQ:\u202fAZN) granting AZ the remaining 50% China rights for C\u2011CAR031, an autologous GPC3\u2011targeting CAR\u2011T therapy, giving AZ exclusive global development, manufacturing, and commercialization rights. The deal values the GPC3 program at up to USD\u202f630\u202fmillion, including an undisclosed upfront payment and milestones.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54748#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54748\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54748#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1901-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1901-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"AstraZeneca Secures Full Global Rights to AbelZeta\u2019s C\u2011CAR031 in $630M CAR\u2011T Deal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54748#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca Secures Full Global Rights to AbelZeta\u2019s C\u2011CAR031 in $630M CAR\u2011T Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca Secures Full Global Rights to AbelZeta\u2019s C\u2011CAR031 in $630M CAR\u2011T Deal - Insight, China&#039;s Pharmaceutical Industry","description":"AbelZeta Pharma, Inc. (Sino\u2011US biotech) announced an agreement with AstraZeneca (AZ, NASDAQ:\u202fAZN) granting AZ the remaining 50% China rights for C\u2011CAR031, an autologous GPC3\u2011targeting CAR\u2011T therapy, giving AZ exclusive global development, manufacturing, and commercialization rights. The deal values the GPC3 program at up to USD\u202f630\u202fmillion, including an undisclosed upfront payment and milestones.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54748","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca Secures Full Global Rights to AbelZeta\u2019s C\u2011CAR031 in $630M CAR\u2011T Deal","og_description":"AbelZeta Pharma, Inc. (Sino\u2011US biotech) announced an agreement with AstraZeneca (AZ, NASDAQ:\u202fAZN) granting AZ the remaining 50% China rights for C\u2011CAR031, an autologous GPC3\u2011targeting CAR\u2011T therapy, giving AZ exclusive global development, manufacturing, and commercialization rights. The deal values the GPC3 program at up to USD\u202f630\u202fmillion, including an undisclosed upfront payment and milestones.","og_url":"https:\/\/flcube.com\/?p=54748","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-19T16:19:42+00:00","article_modified_time":"2026-01-19T16:19:43+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1901-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54748#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54748"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca Secures Full Global Rights to AbelZeta\u2019s C\u2011CAR031 in $630M CAR\u2011T Deal","datePublished":"2026-01-19T16:19:42+00:00","dateModified":"2026-01-19T16:19:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54748"},"wordCount":438,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=54748#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1901-1.webp","keywords":["AbelZeta Pharma","AstraZeneca","Cancer","CAR-T","Cell-therapy","NASDAQ: AZN"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54748#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54748","url":"https:\/\/flcube.com\/?p=54748","name":"AstraZeneca Secures Full Global Rights to AbelZeta\u2019s C\u2011CAR031 in $630M CAR\u2011T Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=54748#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=54748#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1901-1.webp","datePublished":"2026-01-19T16:19:42+00:00","dateModified":"2026-01-19T16:19:43+00:00","description":"AbelZeta Pharma, Inc. (Sino\u2011US biotech) announced an agreement with AstraZeneca (AZ, NASDAQ:\u202fAZN) granting AZ the remaining 50% China rights for C\u2011CAR031, an autologous GPC3\u2011targeting CAR\u2011T therapy, giving AZ exclusive global development, manufacturing, and commercialization rights. The deal values the GPC3 program at up to USD\u202f630\u202fmillion, including an undisclosed upfront payment and milestones.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54748#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54748"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=54748#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1901-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1901-1.webp","width":1080,"height":608,"caption":"AstraZeneca Secures Full Global Rights to AbelZeta\u2019s C\u2011CAR031 in $630M CAR\u2011T Deal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54748#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca Secures Full Global Rights to AbelZeta\u2019s C\u2011CAR031 in $630M CAR\u2011T Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1901-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54748"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54748\/revisions"}],"predecessor-version":[{"id":54752,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54748\/revisions\/54752"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/54751"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}